0.7065USD+2.39%Mkt Cap: 13.56M USDP/E: —Last update: 2026-05-26
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap13.56M USD
Enterprise Value4.05M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.47M USD
Revenue/Share—
Last Price0.7065 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.90
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.62
EPS (TTM)-0.80
EPS (Forward)-0.71
52W Range
0.489013% of range2.115
52W High2.115 USD
52W Low0.4890 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-202.73%
ROA-164.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.80M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-40.88%
Net Debt-6.24M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio4.72
Quick Ratio4.30
Book Value/Sh0.3960 USD
Cash/Share0.3840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateOct 26, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.19.13M
Float15.79M
Insiders2.89%
Institutions4.11%
Short Interest
Short Ratio0.1d
Short % Float4.29%
Short % Out.4.17%
Shares Short797.31K
Short (prev mo.)749.81K
Technical
SMA 500.7406 (-4.6%)
SMA 2001.114 (-36.6%)
Beta0.58
S&P 52W Chg28.31%
Avg Vol (30d)4.27M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—